Table 2.
Association of POU6F2-AS and AC022162.1 expression with baseline characteristics of NSCLC patients in validation cohort.
| Variable | N (%) | POU6F2-AS2 | AC022162.1 | ||
|---|---|---|---|---|---|
| n (%) | Mean | p | Mean | p | |
| Age | |||||
| <66 years | 38 (45.2) | 9.5 | 0.686 | 9.6 | 0.438 |
| ≥66 years | 46 (54.8) | 9.6 | 9.9 | ||
| Gender | |||||
| Male | 42 (50) | 9.8 | 0.058 | 9.9 | 0.430 |
| Female | 42 (50) | 9.3 | 9.6 | ||
| Smoking | |||||
| Never smoker | 5 (6) | 9.2 | 0.833 | 9.8 | 0.865 |
| Past smoker | 18 (21) | 9.5 | 10.1 | ||
| Current smoker | 14 (17) | 9.6 | 9.6 | ||
| Unknown | 47 (56) | 9.7 | 9.7 | ||
| ECOG status | |||||
| 0 | 64 (76) | 9.5 | 0.517 | 9.6 | 0.355 |
| 1 | 16 (19) | 9.9 | 10.3 | ||
| 2 | 1 (1) | 10.9 | 11.4 | ||
| Unknown | 3 (4) | 9.7 | 9.6 | ||
| Histology | |||||
| Adenocarcinoma | 23 (27) | 9.6 | 0.942 | 9.9 | 0.913 |
| Non-squamous NSCLC | 33 (39) | 9.5 | 9.6 | ||
| Squamous NSCLC | 21 (25) | 9.7 | 9.9 | ||
| Other | 7 (8) | 9.7 | 9.7 | ||
| Stage | |||||
| Early (I-II) | 33 (39) | 9.4 | 0.264 | 9.7 | 0.854 |
| Late (III-IV) | 51 (61) | 9.7 | 9.8 | ||
| CEA | |||||
| <ULN | 9 (11) | 9.2 | 0.371 | 9.1 | 0.467 |
| ≥ULN | 32 (38) | 9.8 | 9.8 | ||
| Not done | 43 (51) | 9.5 | 9.9 | ||
| Cyfra21-1 | |||||
| <ULN | 5 (6) | 8.2 | 0.017 | 8.3 | 0.151 |
| ≥ULN | 36 (43) | 9.9 | 9.9 | ||
| Not done | 43 (51) | 9.5 | 9.9 | ||
p: student’s t-test (2-groups) or 1-way ANOVA (3 or more groups); Mean values represent log2 RNA copies/ml plasma; CEA ULN (upper limit of normal): 2.6 ng/ML; Cyfra21-1 ULN (upper limit of normal): 2.1 ng/ML; NSCLC, non-small cell lung cancer.